Biofrontera Inc. (BFRI)
Automate Your Wheel Strategy on BFRI
With Tiblio's Option Bot, you can configure your own wheel strategy including BFRI - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol BFRI
- Rev/Share 0.0043
- Book/Share 0.0001
- PB 11545.5721
- Debt/Equity 10.3689
- CurrentRatio 1.399
- ROIC -2.695
- MktCap 5764069.0
- FreeCF/Share -0.0012
- PFCF -0.5232
- PE -469.8372
- Debt/Assets 0.2932
- DivYield 0
- ROE -2.16
- Rating D+
- Score 1
- Recommendation Strong Sell
- P/E Score 1
- DCF Score 1
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| No ratings available. | |||||||
News
Biofrontera Inc. (BFRI) Q1 2025 Earnings Call Transcript
Published: May 16, 2025 by: Seeking Alpha
Sentiment: Neutral
Biofrontera Inc. (NASDAQ:BFRI ) Q1 2025 Earnings Conference Call May 16, 2025 10:00 AM ET Company Participants Andrew Barwicki - IR Representative Hermann Luebbert - CEO, Chairman, & Founder Fred Leffler - CFO Conference Call Participants Jonathan Aschoff - ROTH Capital Bruce Jackson - The Benchmark Company Operator Good day, and welcome to the Biofrontera's First Quarter 2025 Financial Results and Business Update Conference Call. All participants will be in listen-only mode.
Read More
Biofrontera Inc. Announces New Patent Protection on Ameluz® until 2043 and the Completion of Patient Enrollment in Phase 2b Study of Ameluz® (aminolevulinic acid HCI) Topical Gel, 10% for the Treatment of Moderate to Severe Acne Vulgaris
Published: May 15, 2025 by: GlobeNewsWire
Sentiment: Neutral
WOBURN, Mass., May 15, 2025 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company focused on the development and commercialization of photodynamic therapy (PDT), received confirmation that the updated formulation of the Ameluz® nanoemulsion gel without propylene glycol received patent approval through to December 2043. The formulation was earlier accepted for use in Ameluz® by the US Food and Drug Administration (FDA) and is in use since 2024. In addition to this long-lasting protection of Ameluz® against generic competition, Biofrontera today announced the successful enrollment of the final patient in its Phase 2b clinical trial evaluating Ameluz® (aminolevulinic acid …
Read More
Biofrontera Inc. to Report First Quarter FY 2025 Financial Results on May 15, 2025
Published: May 06, 2025 by: Accesswire
Sentiment: Neutral
WOBURN, MA / ACCESS Newswire / May 6, 2025 / Biofrontera Inc. (Nasdaq:BFRI) ("Biofrontera" or the "Company"), a biopharmaceutical company specializing in the commercialization of dermatological products, announces it will report financial results for the three months ended March 31, 2025 on Thursday, May 15, 2025. The results will be released after the market close on Thursday, May 15 and the company will host a conference call on Friday, May 16 at 10:00am Eastern Time.
Read More
Biofrontera and Almirall Launch the Hats On Challenge to Raise Awareness and Support for Actinic Keratosis
Published: May 01, 2025 by: GlobeNewsWire
Sentiment: Neutral
Woburn, Mass., May 01, 2025 (GLOBE NEWSWIRE) -- Biofrontera Inc. (NASDAQ:BFRI), a biopharmaceutical company specializing in the development and commercialization of photodynamic therapy (PDT), and Almirall, a global pharmaceutical company dedicated to medical dermatology announced today the launch of the Hats On Challenge, a new community-driven, social media based initiative aimed at enhancing awareness and support for actinic keratosis (AK).
Read More
Biofrontera Inc. (BFRI) Q4 2024 Earnings Call Transcript
Published: March 21, 2025 by: Seeking Alpha
Sentiment: Neutral
Biofrontera Inc. (NASDAQ:BFRI ) Q4 2024 Earnings Conference Call March 21, 2025 10:00 AM ET Company Participants Andrew Barwicki - IR Representative Hermann Luebbert - CEO, Chairman, and Founder Fred Leffler - CFO Conference Call Participants Jonathan Aschoff - Roth Capital Bruce Jackson - The Benchmark Company Operator Good morning and welcome to the Biofrontera Fourth Quarter and Fiscal 2024 Financial Results and Business Update Conference Call. All participants will be in listen-only mode.
Read More
Biofrontera Inc. Announces Completion of Patient Enrollment in Phase 3 Study of Ameluz® (aminolevulinic acid HCI) Topical Gel, 10% for the Treatment of Actinic Keratoses on the Extremities, Neck and Trunk
Published: March 18, 2025 by: GlobeNewsWire
Sentiment: Neutral
WOBURN, Mass., March 18, 2025 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI) (“Biofrontera” or the “Company”), a biopharmaceutical company specializing in the development and commercialization of photodynamic therapy (PDT), today announced the enrollment of the final patient in its Phase 3 clinical trial evaluating Ameluz® (aminolevulinic acid hydrochloride) for the treatment of mild to moderate actinic keratoses (AKs) on the extremities, neck and trunk. Actinic keratosis is a common skin condition found on sun-exposed areas of the body, and if left untreated, may progress to squamous cell carcinoma. Expanding field treatment options for AKs beyond the face and scalp would …
Read More
Biofrontera Inc. to Report Fourth Quarter and Full Year 2024 Financial Results on March 21, 2025
Published: March 11, 2025 by: GlobeNewsWire
Sentiment: Neutral
WOBURN, Mass., March 11, 2025 (GLOBE NEWSWIRE) -- Biofrontera Inc. (NASDAQ:BFRI), a biopharmaceutical company specializing in the development and commercialization of dermatological products, today announced that it will report financial results for the three and 12 months ended December 31, 2024 on Friday, March 21, 2025. The results will be released before the market opens on Friday, March 21 and the company will host a conference call on Friday, March 21 at 10:00am Eastern Time.
Read More
About Biofrontera Inc. (BFRI)
- IPO Date 2021-10-29
- Website https://www.biofrontera.us.com
- Industry Drug Manufacturers - Specialty & Generic
- CEO Dr. Hermann Luebbert Ph.D.
- Employees 92